farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLC10.17749/2070-4909/farmakoekonomika.2025.326farmaec-1244Research ArticleREVIEW ARTICLESОБЗОРНЫЕ ПУБЛИКАЦИИCost and clinical effectiveness of fixed-dose combination therapies in the treatment of glaucoma patients: a systematic reviewСистематический обзор экономической и клинической эффективности препаратов, используемых при лечении больных с глаукомойhttps://orcid.org/0000-0003-4106-0395УмароваШ. З.UmarovaSh. Z.

Умарова Шахноз Зиятовна, д.м.н., проф. 

Юнусабадский р-н, квартал 19, ул. Дехканабад, д. 46–48, Ташкент 100114

Shakhnoz Z. Umarova, Dr. Sci. Med., Prof. 

46-48 Dekhkanabad Str., Quarter 19, Yunusabad District, Tashkent 100114, Republic of Uzbekistan

https://orcid.org/0000-0001-8822-8015УсмоноваЗ. Р.UsmonovaZ. R.

Усмонова Зоя Рустам кизи 

Юнусабадский р-н, квартал 19, ул. Дехканабад, д. 46–48, Ташкент 100114

Zoya R. Usmonova 

46-48 Dekhkanabad Str., Quarter 19, Yunusabad District, Tashkent 100114, Republic of Uzbekistan

https://orcid.org/0009-0008-0158-5529НорматоваН. М.NormatovaN. M.

Норматова Наргиза Миршавкатовна, д.м.н., доцент 

ул. Паркентская, д. 51, Ташкент 100007

Nargiza M. Normatova, Dr. Sci. Med., Assoc. Prof.

51 Parkentskaya Str., Tashkent 100007 

https://orcid.org/0000-0002-1658-7972СултанбаеваН. М.SultanbayevaN. M.

Султанбаева Наргиза Мухамед Умаровна, доктор философии

Юнусабадский р-н, квартал 19, ул. Дехканабад, д. 46–48, Ташкент 100114

Nargiza М. Sultanbayeva, PhD

46-48 Dekhkanabad Str., Quarter 19, Yunusabad District, Tashkent 100114, Republic of Uzbekistan

nargiz6985@gmail.comФармацевтический институт образования и исследованийУзбекистанInstitute of Pharmaceutical Education and ResearchUzbekistanЦентр развития профессиональной квалификации медицинских работниковУзбекистанCenter for the Development of Professional Qualifications of Medical WorkersUzbekistan202522102025183429436Copyright © Umarova S.Z., Usmonova Z.R., Normatova N.M., Sultanbayeva N.M., 20252025Умарова Ш.З., Усмонова З.Р., Норматова Н.М., Султанбаева Н.М.Umarova S.Z., Usmonova Z.R., Normatova N.M., Sultanbayeva N.M.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/1244Background

Background. Primary open-angle glaucoma (POAG) is a chronic, progressive eye condition causing optic nerve damage and irreversible vision loss by increasing intraocular pressure (IOP). Therapy primarily aimed at reducing IOP to prevent disease progression. Pharmacoeconomic evaluation of fixed-dose combinations (FDCs) has attracted growing interest in recent years as a strategy to enhance both treatment efficacy and accessibility.

Objective

Objective: To review the cost and clinical effectiveness for FDCs of travoprost/timolol (TT) and latanoprost/timolol (LT) for POAG treatment.

Material and methods

Material and methods. A systematic literature review was conducted using PubMed/MEDLINE, Web of Science, ScienceDirect, and Google Scholar databases. The sampling included studies evaluating FDCs of TT and LT in terms of its cost and clinical effectiveness, as well as cost-effectiveness and cost-utility ratios.

Results

Results. TT-FCD proved to be more cost-effective than LT-FDC in several European countries and the Philippines, resulting in lower long-term costs and slowing the progression of vision loss. Conversely, in China identified LT-FDC was more cost-effective due to lower daily costs. Both FDC options improved patient adherence to treatment due to their simplified administration.

Conclusion

Conclusion. TT-FCD may be a more favorable treatment option for POAG in certain regions, considering its pharmacoeconomic and clinical advantages. However, treatment selection should be individualized based on regional healthcare dynamics, medicine pricing, and patient access to medicines.

Актуальность

Актуальность. Первичная открытоугольная глаукома (ПОУГ) – хроническое прогрессирующее заболевание, характеризующееся повышением внутриглазного давления (ВГД), что может привести к повреждению зрительного нерва и необратимой потере зрения. Основной целью терапии является снижение ВГД для предотвращения прогрессирования патологии. В последние годы растет интерес к фармакоэкономической оценке фиксированных комбинаций (ФК) препаратов как способа повышения эффективности и доступности лечения.

Цель

Цель: провести систематический обзор экономической и клинической эффективности ФК «травопрост + тимолол» (ТТ) и «латанопрост + тимолол» (ЛТ) при лечении ПОУГ.

Материал и методы

Материал и методы. Выполнен систематический обзор публикаций, найденных в базах данных PubMed/MEDLINE, Web of Science, ScienceDirect и Google Scholar. В анализ включены исследования, оценивающие стоимость, клиническую эффективность, показатели «затраты – эффективность» и «затраты – полезность» комбинаций ТТ и ЛТ.

Результаты

Результаты. ФК ТТ показала более высокую экономическую эффективность по сравнению с ЛТ в странах Европы и на Филиппинах, обеспечивая более низкие долгосрочные затраты и замедляя прогрессирование потери зрения. В Китае, напротив, применение ЛТ оказалось более экономически оправданным за счет более низких ежедневных расходов. Оба варианта ФК улучшали приверженность пациентов к лечению за счет удобства применения.

Заключение

Заключение. ФК ТТ может быть предпочтительным вариантом терапии ПОУГ с точки зрения фармакоэкономики и клинической эффективности в ряде регионов. Однако выбор конкретной схемы лечения должен учитывать региональные особенности, стоимость препаратов и доступность для пациентов.

глаукоматравопростлатанопросттимололфиксированные комбинацииэкономическая эффективностьфармакоэкономикаglaucomatravoprostlatanoprosttimololfixed-dose combinationscost-effectivenesspharmacoeconomicsReferencesNeelakantan A., Vaishnav H.D, Iyer S.A, Sherwood M.B. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004; 13 (2): 130–6. https://doi.org/10.1097/00061198-200404000-00008.Neelakantan A., Vaishnav H.D, Iyer S.A, Sherwood M.B. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004; 13 (2): 130–6. https://doi.org/10.1097/00061198-200404000-00008.Еричев В.П. Современные принципы гипотензивной терапии глаукомы. В кн.: Научно-практическая конференция «Глаукома: реальность и перспективы»: сборник научных статей. Москва, 25–26 сентября 2008 г. М.; 2008: 220–3.Erichev V.P. Modern principles of hypotensive therapy of glaucoma. In: Scientific and practical conference “Glaucoma: reality and prospects”: collection of scientific articles. Moscow, September 25–26, 2008. Мoscow; 2008: 220–3 (in Russ.).European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th ed. Savona, Italy: PubliComm; 2014. https://doi.org/10.1136/bjophthalmol-2016-egsguideline.001.European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th ed. Savona, Italy: PubliComm; 2014. https://doi.org/10.1136/bjophthalmol-2016-egsguideline.001.Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120 (6): 701–13. https://doi.org/10.1001/archopht.120.6.701.Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120 (6): 701–13. https://doi.org/10.1001/archopht.120.6.701.Еричев В.П., Дугина А.Е., Мазурова Ю.В. Фиксированные лекарственные формы: современный подход к терапии глаукомы. Глаукома. 2010; 1: 62–5.Erichev V.P., Dugina A.E., Mazurova Yu.V. Fixed combinations in glaucoma treatment: particular case. Glaucoma. 2010; 1: 62–5 (in Russ.).Куроедов А.В. Перспективы применения комбинированных антиглаукомных препаратов (обзор литературы). Русский медицинский журнал. 2007; 4: 176–81.Kuroyedov A.V. Prospects of combined antiglaucoma drugs usage (literary review). Russian Medical Journal. 2007; 4: 176–81 (in Russ.).Robin A.L., Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005; 112 (5): 863–8. https://doi.org/10.1016/j.ophtha.2004.12.026.Robin A.L., Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005; 112 (5): 863–8. https://doi.org/10.1016/j.ophtha.2004.12.026.Van Wijk B.L., Klungel O.H., Heerdink E.R., de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005; 23 (11): 2101–7. https://doi.org/10.1097/01.hjh.0000187261.40190.2e.Van Wijk B.L., Klungel O.H., Heerdink E.R., de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005; 23 (11): 2101–7. https://doi.org/10.1097/01.hjh.0000187261.40190.2e.Guven S., Koylu M.T., Mumcuoglu T. Adherence to glaucoma medication, illness perceptions, and beliefs about glaucoma: attitudinal perspectives among Turkish population. Eur J Ophthalmol. 2021; 31 (2): 469–76. https://doi.org/10.1177/1120672120901687.Guven S., Koylu M.T., Mumcuoglu T. Adherence to glaucoma medication, illness perceptions, and beliefs about glaucoma: attitudinal perspectives among Turkish population. Eur J Ophthalmol. 2021; 31 (2): 469–76. https://doi.org/10.1177/1120672120901687.Robin A., Grover D.S. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011; 59 (Suppl. 1): S93–6. https://doi.org/10.4103/0301-4738.73693.Robin A., Grover D.S. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011; 59 (Suppl. 1): S93–6. https://doi.org/10.4103/0301-4738.73693.Tsai J.C., McClure C.A., Ramos S.E., et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003; 12 (5): 393–8. https://doi.org/10.1097/00061198-200310000-00001.Tsai J.C., McClure C.A., Ramos S.E., et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003; 12 (5): 393–8. https://doi.org/10.1097/00061198-200310000-00001.Newman-Casey P.A., Robin A.L., Blachley T., et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015; 122 (7): 1308–16. https://doi.org/10.1016/j.ophtha.2015.03.026.Newman-Casey P.A., Robin A.L., Blachley T., et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015; 122 (7): 1308–16. https://doi.org/10.1016/j.ophtha.2015.03.026.Barnebey H.S., Robin A.L. Adherence to fixed-combination versus unfixed travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017; 176: 61–9. https://doi.org/10.1016/j.ajo.2016.12.002.Barnebey H.S., Robin A.L. Adherence to fixed-combination versus unfixed travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017; 176: 61–9. https://doi.org/10.1016/j.ajo.2016.12.002.Windham B.G., Griswold M.E., Fried L.P., et al. Impaired vision and the ability to take medications. J Am Geriatr Soc. 2005; 53 (7): 1179–90. https://doi.org/10.1111/j.1532-5415.2005.53376.x.Windham B.G., Griswold M.E., Fried L.P., et al. Impaired vision and the ability to take medications. J Am Geriatr Soc. 2005; 53 (7): 1179–90. https://doi.org/10.1111/j.1532-5415.2005.53376.x.Stewart W.C., Konstas A.G.P., Pfeiffer N. Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. J Ocul Pharmacol Ther. 2004; 20 (6): 461–9. https://doi.org/10.1089/jop.2004.20.461.Stewart W.C., Konstas A.G.P., Pfeiffer N. Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. J Ocul Pharmacol Ther. 2004; 20 (6): 461–9. https://doi.org/10.1089/jop.2004.20.461.Higginbotham E.J., Hansen J., Davis E.J. et al. Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr Med Res Opin. 2009; 25 (10): 2543–7. https://doi.org/10.1185/03007990903260129.Higginbotham E.J., Hansen J., Davis E.J. et al. Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr Med Res Opin. 2009; 25 (10): 2543–7. https://doi.org/10.1185/03007990903260129.Nixon D. Randomized, parallel comparison of the efficacy and tolerability of twice-daily Combigan® vs. Cosopt® fixed-combination therapies in patients with glaucoma or ocular hypertension. In: World Glaucoma Congress. Singapore, July 18–21, 2007. Abstracts book. Geneva; 2007: 171.Nixon D. Randomized, parallel comparison of the efficacy and tolerability of twice-daily Combigan® vs. Cosopt® fixed-combination therapies in patients with glaucoma or ocular hypertension. In: World Glaucoma Congress. Singapore, July 18–21, 2007. Abstracts book. Geneva; 2007: 171.Rossi G.C., Pasinetti G.M., Scudeller L., et al. Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination. Expert Opin Pharmacother. 2010; 11 (4): 499–504. https://doi.org/10.1517/14656561003601994.Rossi G.C., Pasinetti G.M., Scudeller L., et al. Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination. Expert Opin Pharmacother. 2010; 11 (4): 499–504. https://doi.org/10.1517/14656561003601994.Noecker R.J., Awadallah N.S., Kahook M.Y. Travoprost 0.004%/timolol 0.5% fixed combination. Drugs Today. 2007; 43 (2): 77–83. https://doi.org/10.1358/dot.2007.43.2.1032058.Noecker R.J., Awadallah N.S., Kahook M.Y. Travoprost 0.004%/timolol 0.5% fixed combination. Drugs Today. 2007; 43 (2): 77–83. https://doi.org/10.1358/dot.2007.43.2.1032058.Herceg M., Noecker R. Travoprost/timolol fixed combination. Expert Opin Pharmacother. 2008; 9 (6): 1059–65. https://doi.org/10.1517/14656566.9.6.1059.Herceg M., Noecker R. Travoprost/timolol fixed combination. Expert Opin Pharmacother. 2008; 9 (6): 1059–65. https://doi.org/10.1517/14656566.9.6.1059.Zhao J.L., Ge J., Li X.X., et al. Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. BMC Ophthalmol. 2011; 11: 23. https://doi.org/10.1186/1471-2415-11-23.Zhao J.L., Ge J., Li X.X., et al. Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. BMC Ophthalmol. 2011; 11: 23. https://doi.org/10.1186/1471-2415-11-23.Schmier J.K., Halpern M.T., Covert D.W, Robin A.L. Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression. Curr Med Res Opin. 2006; 22 (9): 1737–43. https://doi.org/10.1185/030079906X121011.Schmier J.K., Halpern M.T., Covert D.W, Robin A.L. Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression. Curr Med Res Opin. 2006; 22 (9): 1737–43. https://doi.org/10.1185/030079906X121011.Hommer A., Wickstrøm J., Friis M.M., et al. A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective. Curr Med Res Opin. 2008; 24 (4): 1057–63. https://doi.org/10.1185/030079908X280626.Hommer A., Wickstrøm J., Friis M.M., et al. A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective. Curr Med Res Opin. 2008; 24 (4): 1057–63. https://doi.org/10.1185/030079908X280626.Bergström A., Maurel F., Le Pen C., et al. Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden. Clin Ophthalmol. 2009: 3: 471–81. https://doi.org/10.2147/opth.s6811.Bergström A., Maurel F., Le Pen C., et al. Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden. Clin Ophthalmol. 2009: 3: 471–81. https://doi.org/10.2147/opth.s6811.Azarcon C.P., Florcruz N.V.D.G. The daily, monthly, and annual cost of glaucoma therapy using ocular hypotensive eye drops in the Philippines based on a quantitative method. Philippine J Ophthalmol. 2020; 45 (2): 84–96.Azarcon C.P., Florcruz N.V.D.G. The daily, monthly, and annual cost of glaucoma therapy using ocular hypotensive eye drops in the Philippines based on a quantitative method. Philippine J Ophthalmol. 2020; 45 (2): 84–96.Xu C., Guo R., Huang D., et al. Daily costs and cost effectiveness of glaucoma fixed combinations in China. J Ophthalmol. 2020; 2020: 2406783. https://doi.org/10.1155/2020/2406783.Xu C., Guo R., Huang D., et al. Daily costs and cost effectiveness of glaucoma fixed combinations in China. J Ophthalmol. 2020; 2020: 2406783. https://doi.org/10.1155/2020/2406783.Patel A.R., Schwartz G.F., Campbell J.H., et al. Economic and clinical burden associated with intensification of glaucoma topical therapy: a us claims-based analysis. J Glaucoma. 2021; 30 (3): 242–50. https://doi.org/10.1097/IJG.0000000000001730.Patel A.R., Schwartz G.F., Campbell J.H., et al. Economic and clinical burden associated with intensification of glaucoma topical therapy: a us claims-based analysis. J Glaucoma. 2021; 30 (3): 242–50. https://doi.org/10.1097/IJG.0000000000001730.Fujita A., Hashimoto Y., Okada A., et al. Practice patterns and costs of glaucoma treatment in Japan. Jpn J Ophthalmol. 2023; 67 (5): 590–601. https://doi.org/10.1007/s10384-023-01002-w.Fujita A., Hashimoto Y., Okada A., et al. Practice patterns and costs of glaucoma treatment in Japan. Jpn J Ophthalmol. 2023; 67 (5): 590–601. https://doi.org/10.1007/s10384-023-01002-w.Петров С.Ю., Якубова Л.В., Маркелова О.И. Современные тенденции в лечении глаукомы. Российский офтальмологический журнал. 2024; 17 (1): 136–43. https://doi.org/10.21516/2072-0076-2024-17-1-136-143.Petrov S.Yu., Yakubova L.V., Markelova O.I. Modern trends in the treatment of glaucoma. Russian Ophthalmological Journal. 2024; 17 (1): 136–43 (in Russ.). https://doi.org/10.21516/2072-0076-2024-17-1-136-143.Tuulonen A. Cost-effectiveness of screening for open angle glaucoma in developed countries. Indian J Ophthalmol. 2011; 59 (Suppl. 1): S24–30. https://doi.org/10.4103/0301-4738.73684.Tuulonen A. Cost-effectiveness of screening for open angle glaucoma in developed countries. Indian J Ophthalmol. 2011; 59 (Suppl. 1): S24–30. https://doi.org/10.4103/0301-4738.73684.Ofei-Palm C.N.K., Tagoe N.N., Jatoe D., et al. Сost analysis and rational use of anti-glaucoma therapy in a tertiary hospital in Ghana. Clinicoecon Outcomes Res. 2021; 13: 619–27. https://doi.org/10.2147/CEOR.S311058.Ofei-Palm C.N.K., Tagoe N.N., Jatoe D., et al. Сost analysis and rational use of anti-glaucoma therapy in a tertiary hospital in Ghana. Clinicoecon Outcomes Res. 2021; 13: 619–27. https://doi.org/10.2147/CEOR.S311058.Kernohan A., Homer T., Shabaninejad H., et al. Cost-effectiveness of primary surgical versus primary medical management in the treatment of patients presenting with advanced glaucoma. Br J Ophthalmol. 2023; 107 (10): 1452–7. https://doi.org/10.1136/bjophthalmol-2021-320887.Kernohan A., Homer T., Shabaninejad H., et al. Cost-effectiveness of primary surgical versus primary medical management in the treatment of patients presenting with advanced glaucoma. Br J Ophthalmol. 2023; 107 (10): 1452–7. https://doi.org/10.1136/bjophthalmol-2021-320887.

The authors declare that there are no conflicts of interest present.